K-V Pharmaceutical Co - FORM 10-Q - EX-32.2 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - March 10, 2011

Attached files

file filename
10-Q - FORM 10-Q - K-V Pharmaceutical Cod10q.htm
EX-10.6 - AMENDMENT NO. 2 TO CREDIT AGREEMENT - K-V Pharmaceutical Codex106.htm
EX-10.3 - RESTATED STOCK PURCHASE WARRANT NO. W-1 - K-V Pharmaceutical Codex103.htm
EX-10.4 - RESTATED STOCK PURCHASE WARRANT NO. W-2 - K-V Pharmaceutical Codex104.htm
EX-10.1 - WAIVER TO CREDIT AGREEMENT - K-V Pharmaceutical Codex101.htm
EX-10.2 - STOCK WARRANT PURCHASE AGREEMENT - K-V Pharmaceutical Codex102.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER, SECTION 302 - K-V Pharmaceutical Codex312.htm
EX-10.5 - STOCK PURCHASE WARRANT NO. W-3 - K-V Pharmaceutical Codex105.htm
EX-10.7 - SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT - K-V Pharmaceutical Codex107.htm
EX-32.1 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - K-V Pharmaceutical Codex321.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER, SECTION 302 - K-V Pharmaceutical Codex311.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of K-V Pharmaceutical Company (the “Company”) on Form 10-Q for the quarter ended June 30, 2010, as filed with the Securities and Exchange Commission (the “Report”), I, Thomas S. McHugh, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 10, 2011

 

/s/ Thomas S. McHugh

Thomas S. McHugh

Chief Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished to the Securities and Exchange Commission as our exhibit to the Quarterly Report on Form 10-Q and shall not be deemed to be considered filed as part of the Quarterly Report on Form 10-Q.

K-V Pharmaceutical Co Reports